Bain Capital Sells $131.4M in Shares, Drops Below 5% Ownership
NAMS has more than doubled off its 52-week low of $16.785.
Summary
Bain Capital Life Sciences has sold $131.4 million in NewAmsterdam Pharma shares, reducing its stake to below 5% beneficial ownership.
Key Events · Ownership and Investor Activity · NAMS
-
Major Stake Reduction
Bain Capital Life Sciences entities sold 3.5 million Ordinary Shares across three transactions from May 8-12, 2026.
-
Significant Proceeds
The sales generated aggregate proceeds of approximately $131.4 million, with shares sold at weighted average prices between $37.22 and $39.98.
-
Below 5% Ownership
Following these sales, Bain Capital Life Sciences collectively ceased to beneficially own 5% or more of NewAmsterdam Pharma's outstanding Ordinary Shares, now holding approximately 3.3%.
Analysis · NAMS · Life Sciences
Bain Capital Life Sciences entities have significantly reduced their stake in NewAmsterdam Pharma, selling approximately $131.4 million worth of shares over three days. This substantial disposition has caused the investment group to cease being a 5% beneficial owner. This marks a major reduction in their position and reinforces a broader distribution trend seen in recent insider activity.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 34.9% of the 999 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NAMS was trading at $33.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $16.79 to $42.21. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.